Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Acura Pharmaceuticals announces settlement of patent litigation with Sandoz
In the suit, Acura alleges that a generic of Acura’s AVERSION oxycodone product, previously marketed by Pfizer Inc. under its brand name OXECTA, for which Sandoz is seeking
In the suit, Acura alleges that a generic of Acura’s AVERSION oxycodone product, previously marketed by Pfizer Inc. under its brand name OXECTA, for which Sandoz is seeking
Developed by PAREXEL Informatics, it is a key component of the Perceptive MyTrials eClinical platform, an integrated suite of applications for managing clinical trials. On-site monitoring is a
AntiOp founder Dr. Daniel Wermeling said that this partnership leverages the company’s combined resources and strengths. "AntiOp has the technical expertise and R&D experience to deliver a specifically-designed
The aforementioned agreement is another important step moving forward in Argentina and South America pursuant to the company’s sales, marketing, distribution and supply agreement for Ampligen with GP
The FDA is requiring additional time to review supplemental data that Baxter provided as part of the ongoing BLA process for HyQvia approval. The PDUFA date has been
TD2 will study the effectiveness of Nuvilex’s pancreatic cancer treatment in relieving the unbearable pain and the accumulation of abdominal fluid known as ‘ascites’. Nuvilex’s pancreatic cancer treatment,
Leveraging the robust operational data available through the Medidata Clinical Cloud, Medidata is providing metrics and analytics to help TransCelerate answer important questions posed by the industry regarding
SUGARDOWN is Boston Therapeutics’ currently marketed dietary supplement that is intended to support healthy blood sugar. In addition, clinical studies indicate that SUGARDOWN can maintain healthy glucose levels
Ceapro president and CEO Gilles Gagnon said that the signing of this Agreement is a significant milestone for our Company since this technology would allow the development, production
MDX-8704, a fixed-dosed combination (FDC) of memantine HCl extended release capsules and donepezil HCl, is being developed as a once daily therapy for the treatment of moderate-to-severe dementia